More than $582 Billion in New U.S. Investment Since 2025
America leads the world in healthcare innovation and access, and a strong medical infrastructure is essential to maintain this standing for our national security.
The world’s pharmaceutical companies are stepping up their investments in America.
We Work For Health’s tracking tool, the U.S. Biopharma Investment Watch, is documenting these developments and providing visibility into the sector's robust expansion and critical role in securing America's position as the global leader in health care innovation. Since January 2025, companies have committed to investing more than $582 billion to bolster U.S. research and development, expand manufacturing, and create jobs across the country.
Investment in America
These investments bring cutting edge treatments closer to the patients who need them while bolstering America’s position as a world leader in healthcare access and innovation. The positive impact of these investments reaches deep into U.S. communities, powering high-skill positions for scientists and engineers, construction and production support roles, and millions of jobs for the communities surrounding the facilities. This builds upon more than 4.9 million total U.S. jobs and $71.6 billion in vendor spending in states along with $2.6B in wages paid to the American construction workforce.
The tracker reflects the sector’s commitment to preserving American leadership in the life sciences, as China continues a coordinated campaign to overtake it.
1,488%
increase in announced U.S. facility investments in 2025 vs 2024
Tens of Thousands
of new construction jobs across America
Faster delivery
of breakthrough medicines to U.S. patients
It’s essential to have the right policies in place that encourage continued investment to secure America’s future as the global leader in life sciences.
U.S. Biopharma Investment Watch
Legend:
Announcement date
Company
Investment amount
Investment location(s)
Feb 26, 2025
Eli Lilly
$27 billion
Unspecified location
Committed to investing $27 billion to build four new pharmaceutical manufacturing sites in the U.S. over the next five years – which more than doubles its U.S. investment since 2020.
Three of the planned plants will produce active pharmaceutical ingredients, while the fourth will make injectable products.
Site locations will be announced in 2025 and will support a growing pipeline in cardiometabolic disease, oncology, immunology, and neuroscience.
No entries found matching your criteria. Please modify your filters.
Methodology
All investments data comes from publicly available resources. Investments may span across multiple states and, therefore, are reflected on each state page. Investment locations will be updated once specified.
-
Jobs data source: WWFH “in the states” page
-
Labor hours data source: PILMA jobs report page